A new AI tool has been created to help prevent vascular access thrombosis – a major factor in increased suffering and mortality in kidney disease patients requiring haemodialysis.
Renal care provider Diaverum has developed an AI model to support the company’s physicians and nurses predict with a high degree of accuracy, episodes of vascular access thrombosis among haemodialysed patients.
Simulations using Diaverum’s historical patient data predicted an average of 75 per cent of actual cases that were not detected by best-in-class clinical assessments and monitoring systems.
Vascular access (VA) thrombosis is a major factor of suffering and increased mortality for chronic haemodialysis patients, with incidence ranging between 0.11 to 0.5 episodes per patient every year.
It accounts for a significant increase of the total cost of care for these patients, contributing to the unsustainable trajectory of growing expenditure and disease burden impacting national healthcare systems around the world.
Dimitris Moulavasilis, Diaverum’s CEO, said: “VA management is central to our clinical strategy. We are delighted to be announcing today, a breakthrough innovation that will deliver a step-change in our ability to predict and take preventive measures to avoid VA thrombosis episodes among our dialysis patients. It’s a big win for everyone – better digital tools and predictive analytics insights for our healthcare professionals; improved medical outcomes for our patients; and lower cost of care for payors and national health systems.”
Diaverum’s VA model follows the principles of human-centric, explainable, and responsible AI.
READ MORE FROM HT WORLD
The tech that could transform kidney disease treatment and save the NHS millions
It uses personalised input variables comprising dialysis treatment data, lab tests results and demographics, predicting if the patient will suffer from a thrombotic event one week before the episode takes place.
The AI prediction is presented to the nephrologists together with a set of explainable insights, empowering them to offer preventive personalised care to maintain the patient’s vascular access survival.
The new VA AI model is integrated into the company’s digitalised clinical workflows and interfaces with its digital infrastructure, including its proprietary renal information platform, d.CARE, and Treatment Guidance System (TGS).
Starting with its operations in Saudi Arabia, Portugal and Spain, which care for approximately 12,000 renal patients, the company’s objective is to roll out the model to its entire network of 452 clinics in 24 countries, over the next 18 months.
Dr Fernando Macário, Diaverum’s CMO, saidd: “Diaverum’s renal care model is built around safety-oriented policies and procedures, standardised holistic interventions, strong clinical governance and digitalised workflows to deliver medical outcomes that matter for our patients.
“With AI, physicians will have better predictive tools, nurses will come closer to the patients, processes will be more effective and patients will be better treated. Data scientists will be a new subset of healthcare professionals, members of a multidisciplinary team, that will also need to interface with patients and other healthcare professionals, to ensure our focus is always on delivering a personalised, life-enhancing renal care.”